Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-20

Clinical Trial Update: Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating palatability and tolerability of deferasirox when taken with various meals and liquids or crushed into food.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Transfusional Hemosiderosis | Phase 4 | Status: COMPLETED | Results posted: 2021-07-20